Tolerability of NGX-4010, a capsaicin 8% patch for peripheral neuropathic pain.

ABSTRACT:

Background/purpose

NGX-4010 (QUTENZA(™); NeurogesX Inc, San Mateo, CA), a capsaicin 8% dermal patch, is licensed in the European Union for the treatment of peripheral neuropathic pain (PNP) in nondiabetic adults and in the United States for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN). While NGX-4010 treatment is associated with a low risk of systemic adverse events, patch application-related pain is common and may be managed with local cooling and/or oral analgesics. This article characterizes the tolerability of NGX-4010 and will help to guide any pain management.

Methods

This integrated analysis of tolerability data collected from the NGX-4010 clinical study program included 1696 patients with PNP. Patch application-related pain on the tr

SUBMITTER: Peppin JF 

PROVIDER: S-EPMC3255992 | biostudies-literature | 2011

REPOSITORIES: biostudies-literature